Enovis (ENOV) Cash from Financing Activities (2010 - 2026)

Enovis' (ENOV) quarterly Cash from Financing Activities came in at $26.0 million in Q2 2026, down 49.16% year-on-year from $51.2 million in Q2 2025, and up 135.69% on a QoQ basis from -$72.9 million in Q4 2025.

Enovis (ENOV) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Enovis (ENOV) has 17 years of Cash from Financing Activities data on file, last reported at $26.0 million in Q2 2026.

  • On a quarterly basis, Cash from Financing Activities fell 49.16% year-over-year to $26.0 million in Q2 2026; TTM through Apr 2026 was -$77.6 million, a 331.74% decrease from a year earlier, with the FY2025 full-year figure at -$52.4 million, down 106.19% from the prior year.
  • Cash from Financing Activities for Q2 2026 stood at $26.0 million, up from -$72.9 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ENOV reached as high as $864.5 million in Q1 2024 and fell as low as -$495.5 million in Q3 2022.
  • Historically, Cash from Financing Activities has averaged $28.4 million across 5 years, with a median of $2.5 million in 2024.
  • Across the five-year window, Cash from Financing Activities soared 3429.02% in 2024 and plunged 24837.16% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at $41.6 million in 2022, then sank by 93.3% to $2.8 million in 2023, then sank by 819.97% to -$20.1 million in 2024, then tumbled by 263.12% to -$72.9 million in 2025, then surged by 135.69% to $26.0 million in 2026.
  • Per Business Quant data, the three most recent Cash from Financing Activities figures were $26.0 million in Q2 2026, -$72.9 million in Q4 2025, and -$36.9 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 17.31 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -1.51 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn -888.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -260.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -451.20 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -25.00 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -26.93 Mn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 21.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Enovis 1.50 Bn 1.47 Bn 365.49 Mn 26.02 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 26.02 Mn
Apr 3, 2026 26.02 Mn
Dec 31, 2025 -72.92 Mn
Dec 31, 2025 -72.92 Mn
Oct 3, 2025 -36.91 Mn
Oct 3, 2025 -36.91 Mn
Jul 4, 2025 6.23 Mn
Jul 4, 2025 6.23 Mn
Apr 4, 2025 51.19 Mn
Apr 4, 2025 51.19 Mn
Dec 31, 2024 -20.08 Mn
Dec 31, 2024 -20.08 Mn
Sep 27, 2024 -148,000.00
Sep 27, 2024 -148,000.00
Jun 28, 2024 2.51 Mn
Jun 28, 2024 2.51 Mn
Mar 29, 2024 864.54 Mn
Mar 29, 2024 864.54 Mn
Dec 31, 2023 2.79 Mn
Dec 31, 2023 2.79 Mn